Catalent Pharma Solutions has entered into a commercial supply agreement with Vivus, Inc. for Qsymia capsules, a combination phentermine and extended-release topiramate. Catalent will use its drug delivery capabilities and partner with Vivus during the development of Qsymia, including preformulation and formulation, clinical supply and validation. Qsymia was recently approved by the FDA as the first once-daily combination treatment for chronic weight management in adults.   “It is extremely exci...